Back to top

Image: Bigstock

Looking for Value? Why It Might Be Time to Try HCA Healthcare (HCA)

Read MoreHide Full Article

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; HCA Healthcare, Inc. (HCA - Free Report) .

HCA Healthcare in Focus

HCA may be an interesting play thanks to its forward PE of 11.9, its P/S ratio of 0.9, and its decent dividend yield of 1.3%. These factors suggest that HCA Healthcare is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that HCA has decent revenue metrics to back up its earnings.

HCA Healthcare, Inc. PE Ratio (TTM)

But before you think that HCA Healthcare is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 3.7% in the past 30 days, thanks to 13 upward revisions in the past one months compared to none lower.

This estimate strength is actually enough to push HCA to a Zacks Rank #2 (Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So really, HCA Healthcare is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


HCA Healthcare, Inc. (HCA) - free report >>